Pharming Group (NASDAQ: PHAR) — Perfil da empresa, notícias e dados financeiros
Pharming Group develops innovative biopharmaceutical treatments focusing on rare diseases and therapies for hereditary angioedema.
Pharming Group
Pharming Group (EURONEXT:PHARM), (NASDAQ:PHAR) is a biopharmaceutical company engaged in the development, production, and commercialization of innovative treatments for rare diseases and unmet medical needs. Its portfolio focuses on therapies in the fields of hereditary angioedema and Pompe disease, leveraging its expertise in protein replacement therapies. The company is renowned for Ruconest®, its lead product for the treatment of hereditary angioedema. Pharming Group NV is dedicated to enhancing patient care and improving quality of life through continuous research and development. With a commitment to sustainability and ethical practices, Pharming aims to expand its product offering and reach to address the needs of patients globally, striving for excellence in everything they do, with the ultimate goal of becoming a beacon of hope for those facing rare and challenging diseases.
Resumo
Operações
Produtos e/ou serviços de Pharming Group
- Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema treatment.
- Leniolisib, an oral treatment for activated phosphoinositide 3-kinase delta syndrome under investigation.
- Development of an alpha-glucosidase treatment for Pompe disease.
- Innovations in gene therapy aimed at providing long-term solutions for genetic disorders.
- Research in enzyme replacement therapies targeting rare diseases.
- Collaboration on COVID-19 treatment using recombinant human C1 esterase inhibitor.
equipe executiva do Pharming Group
- Kenneth LynardCFO & Co-Chief Executive Officer
- Leverne MarshCo-CEO & Chief Commercial Officer
- Mireille SandersChief Operations Officer
- Michael K. LevitanVP of Investor Relations & Corporate Communications
- Ruud Van OutersterpChief Legal & Compliance Officer and Company Secretary
- Ines BernalChief People Officer
- Anurag RelanChief Medical Officer
- Alexander BreidenbachChief Business Officer
- Magnus HanssonMedical Director
- Bruno M. L. GiannettiConsultant
Últimas notícias sobre a Pharming Group
Pharming revenue rises 21% to $117.6 million
United StatesPharming Q3 revenue surges 21% to $117.6 million
United StatesPharming reports leniolisib Phase II data
United StatesPharming reports positive Phase II results for leniolisib in rare immune disorders
United StatesPharming launches Joenja in Japan for APDS patients
United StatesPharming revenue falls 3% to $90.2 million
United States
Principais indicadores financeiros
Resultados divulgados pela Pharming Group , em USD.
- Cap. de mercado
- 840,1 mi
- Receita (TTM)
- 386,7 mi
- P/L
- 37.1
- LPA (diluído, TTM)
- 0.3
- Dividend yield
- —
- Margem de lucro
- 6.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 376,1 mi | 20,9 mi | 2,9 mi | |
| 297,2 mi | -3,7 mi | -11,8 mi | |
| 245,3 mi | -22,3 mi | -10,5 mi | |
| 205,6 mi | 9,9 mi | 13,7 mi |